KAITLYN REDENIUS: Open Payments
NPI 1255872958 · CAPE CORAL, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$858 in 42 payments from 15 companies in 2025. Trend: 2023 $946 · 2024 $1,219 · 2025 $858
Food & beverage: $858
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $162 |
| Novo Nordisk Inc | 9 | $159 |
| Novartis Pharmaceuticals Corporation | 5 | $121 |
| GlaxoSmithKline, LLC. | 4 | $94 |
| Amgen Inc. | 5 | $80 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $66 |
| Lilly USA, LLC | 1 | $28 |
| Philips North America LLC | 1 | $25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Corcept Therapeutics | 1 | $22 |
Products named: VRAYLAR, LEQVIO, TRELEGY ELLIPTA, Wegovy, OTEZLA, CAPLYTA, Ozempic, Rybelsus.
Industry payments across FL — which companies pay providers there.
